| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d0fc2b70675ee19bd5fc464f5ae9061 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-381 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-381
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2019-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93b944334dbd2eb5696669d5d69b32af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77fc8f76ee9008bab247696a2368405b |
| publicationDate |
2020-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20200059161-A |
| titleOfInvention |
Pharmaceutical composition for enhancing sensitivity to cancer immunotherapy comprising IRE1alpha or XBP1 activation inhibitor |
| abstract |
The present invention relates to a pharmaceutical composition for enhancing the sensitivity to anti-cancer immunotherapy, comprising an active inhibitor of IRE1α or XBP1 as an active ingredient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20220157259-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20230024838-A |
| priorityDate |
2018-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |